News
Tvardi Therapeutics
TVRD · NASDAQ
$0.992+$0.022 (+2.27%)TodayMarket closed ·
Prev close $0.97
Latest news
- Press releaseGlobe Newswire
New Preclinical Data Further Support Potential for Tvardi’s STAT3 Inhibitors in Ulcerative Colitis (UC)
- News
12 Health Care Stocks Moving In Tuesday's After-Market Session
- Press releaseGlobe Newswire
Tvardi Therapeutics Announces Second Quarter 2026 Results and Provides Business Update
- Press releaseGlobe Newswire
Tvardi Therapeutics to Host KOL Webinar on the Clinical Potential of TTI-109 in Ulcerative Colitis (UC) and the Evolving Treatment Landscape, on August 19, 2026
- Press releaseGlobe Newswire
Tvardi Therapeutics Selects Ulcerative Colitis as Initial Indication for TTI-109
- NewsVandana Singh
Why Is Tvardi Therapeutics Stock Falling Thursday?
- NewsVandana Singh
Why Is Tvardi Therapeutics Stock Gaining Tuesday?
- Press releaseGlobe Newswire
Tvardi Therapeutics’ TTI-109 Phase 1 Study Confirms Prodrug Design, Improved Tolerability and Pharmacodynamic Evidence of STAT3 Target Engagement
- Press releaseGlobe Newswire
Tvardi Therapeutics Announces First Quarter 2026 Results and Provides Business Update
- Press releaseGlobe Newswire
Tvardi Therapeutics Announces Fourth Quarter and Full-Year 2025 Results and Provides Business Update
- Press releaseGlobe Newswire
Tvardi Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
- Press releaseGlobe Newswire
Tvardi Therapeutics Announces Further Phase 2 REVERT IPF Data, Expanding Clinical Insights
- Press releasePRNewswire
INVESTIGATION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Tvardi Therapeutics
- Press releaseBusiness Wire
TVRD INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Tvardi Therapeutics
- Press releasePRNewswire
TVRD INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Tvardi Therapeutics
- Press releasePRNewswire
TVRD INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Tvardi Therapeutics
- Press releasePRNewswire
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Tvardi Therapeutics
- Press releasePRNewswire
TVRD INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Tvardi Therapeutics
- Press releasePRNewswire
TVRD INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Tvardi Therapeutics
- Press releaseBusiness Wire
Tvardi Therapeutics to Participate in the Piper Sandler 37th Annual Healthcare Conference
- Press releasePRNewswire
SHAREHOLDER INVESTIGATION: Faruqi & Faruqi, LLP Examining Potential Securities Law Violations at Tvardi
- Press releaseBusiness Wire
Tvardi Therapeutics Announces Third Quarter 2025 Results and Provides Business Update
- Press releaseBusiness Wire
SHAREHOLDER INVESTIGATION: Faruqi & Faruqi, LLP Examining Potential Securities Law Violations at Tvardi
- Press releaseGlobe Newswire
TVRD Investors Have Opportunity to Join Tvardi Therapeutics, Inc. Fraud Investigation with the Schall Law Firm
- Press releaseBusiness Wire
Tvardi Therapeutics to Participate in the Jefferies Global Healthcare Conference in London
- Press releasePRNewswire
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Tvardi Therapeutics
- Press releaseBusiness Wire
TVRD Investors Have Opportunity to Join Tvardi Therapeutics, Inc. Fraud Investigation with the Schall Law Firm
- Press releasePRNewswire
TVRD INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Tvardi Therapeutics
- Press releaseBusiness Wire
Rosen Law Firm Encourages Tvardi Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation – TVRD
- Press releasePRNewswire
Faruqi & Faruqi Reminds Tvardi Therapeutics Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of November 3, 2025 - TVRD
- Press releasePRNewswire
TVRD SHAREHOLDER INVESTIGATION: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Tvardi Therapeutics
- Press releaseBusiness Wire
TVRD INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Tvardi Therapeutics
- NewsAvi Kapoor
Gold Rises Over 3%; Tvardi Therapeutics Shares Plunge
- NewsAvi Kapoor
Dow Surges 1%; Fastenal Shares Fall After Q3 Results
- Press releaseBusiness Wire
Tvardi Therapeutics Provides Update on Preliminary Data from Phase 2 REVERT Trial in Idiopathic Pulmonary Fibrosis
- Press releaseBusiness Wire
Tvardi Therapeutics to Participate in the Cantor Global Healthcare Conference
- Press releaseBusiness Wire
Tvardi Therapeutics Announces Second Quarter 2025 Results and Provides Business Update
- Press releaseBusiness Wire
Tvardi Therapeutics to Participate in the BTIG Virtual Biotechnology Conference
- NewsVandana Singh
Recently Listed Tvardi Therapeutics' Lead Drug 'Positioned To Drive Broad Improvement', Analyst Sees Over 150% Stock Upside
- News
12 Health Care Stocks Moving In Friday's Pre-Market Session
- NewsAvi Kapoor
Why Coursera Shares Are Trading Higher By Over 7%; Here Are 20 Stocks Moving Premarket
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.